Fluoropyrimidine clinical trials
How each study uses Fluoropyrimidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 6
The Netherlands Cancer Institute (2) · Belgian Group of Digestive Oncology (1) · Hoffmann-La Roche (1) · Sanofi (1) · University of Alabama at Birmingham (1) · Nanfang Hospital, Southern Medical University (1) · UNC Lineberger Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Oxaliplatin (3) · Cetuximab (1) · Atezolizumab (1) · Vemurafenib (1) · Bevacizumab (1) · Trastuzumab (1) · Pertuzumab (1) · Cobimetinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Studies
Open first, then newest update. How each study uses Fluoropyrimidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel AdenocarcinomaActive, not recruitingPhase 3Belgian Group of Digestive OncologyNCT04257461Written as Fluoropyrimidine
- A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedPhase 2Hoffmann-La RocheNCT02291289Written as Fluoropyrimidine (5-FU/LV or capecitabine)
- Neoadjuvant Therapy for Localized Rectal AdenocarcinomaWithdrawnPhase 2UNC Lineberger Comprehensive Cancer CenterNCT04418895Written as fluoropyrimidine +/- oxaliplatin
- Improving the Safety of Fluoropyrimidine-based ChemotherapyStatus unknownNot applicableThe Netherlands Cancer InstituteNCT04194957Written as Fluoropyrimidine (capecitabine or 5-fluorouracil)
- Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownPhase 3Nanfang Hospital, Southern Medical UniversityNCT03023436Written as Fluoropyrimidine
- Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of FluoropyrimidinesCompletedNot applicableThe Netherlands Cancer InstituteNCT02324452Written as Fluoropyrimidine (capecitabine or 5-fluorouracil)
- BMS-247550 in Treating Patients With Metastatic Colorectal CancerTerminatedPhase 2University of Alabama at BirminghamNCT00033306Written as Fluoropyrimidine
- TREE-2: Three Regimens of Eloxatin in Advanced Colorectal CancerCompletedPhase 2SanofiNCT00399750Written as fluoropyrimidine
Given beside what is tested · 6 — Fluoropyrimidine is usual care or a partner of the new treatment
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345Written as Fluoropyrimidine
- A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT07818018Written as Fluoropyrimidine
- Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients With GI MalignanciesEnrolling by invitationPhase 2University of Vermont Medical CenterNCT06648785Written as Fluoropyrimidine
- A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerActive, not recruitingPhase 1/2BeiGeneNCT05609370Written as Fluoropyrimidine (FP)
- A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal CancerActive, not recruitingPhase 3Centre Hospitalier Universitaire DijonNCT04188145Written as Fluoropyrimidine
- A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal CancerActive, not recruitingPhase 2/3Seattle Project CorporationNCT05141721Written as Fluoropyrimidine plus leucovorin